Pharmaceuticals Japan

Japan Atopic Dermatitis Drugs Market Analysis, 2024–2034

Updated Reviewed by Vidhi Upadhyay

Japan Atopic Dermatitis Drugs Market Analysis Industry Trends and Forecast to 2034: Segmented by (By Drug Class, By Route of Administration, By Distribution Channel, By Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

Japan · 2024–2034 · placeholder estimates

Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $786.6 Mn Placeholder estimate
Estimate 2025 $886.6 Mn 6.3% of the global market
Projected 2034 $2.60 Bn 193.3% Adds $1.71 Bn over 9 forecast years
CAGR 2025–2034 12.7% Faster than 68% of 180 Pharmaceuticals markets here
Key players 11 +6
  • Japan is 6.27% of the global market.
  • In APAC, the largest is China at $1.17 Bn.
  • Fastest growing: India at 15.2% a year.
  • Japan ranks 2nd of 9 by size in APAC.

Market size projection

Japan

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$1.71 Bn total, 2026–2034

Year-by-year market size, 2024–2034
Atopic Dermatitis Drugs Market market size by year, Japan
YearMarket sizeChange that yearSince 2025
2024 (estimate) $786.6 Mn — —
2025 (base) $886.6 Mn +$99.9 Mn —
2026 (forecast) $999.1 Mn +$112.6 Mn +12.7%
2027 (forecast) $1.13 Bn +$126.9 Mn +27%
2028 (forecast) $1.27 Bn +$143.0 Mn +43.1%
2029 (forecast) $1.43 Bn +$161.2 Mn +61.3%
2030 (forecast) $1.61 Bn +$181.6 Mn +81.8%
2031 (forecast) $1.82 Bn +$204.7 Mn +104.9%
2032 (forecast) $2.05 Bn +$230.7 Mn +130.9%
2033 (forecast) $2.31 Bn +$260.0 Mn +160.3%
2034 (forecast) $2.60 Bn +$293.0 Mn +193.3%

Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Report snapshot

Japan Atopic Dermatitis Drugs Market Analysis at a glance
Market size, 2025$886.6 Mn placeholder estimate
Forecast, 2034$2.60 Bn placeholder estimate
Growth (CAGR), 2025–203412.7% placeholder estimate
Years2024 historical · 2025 base year · 2026–2034 forecast
SegmentsDrug class, route of administration and distribution channel (see all)
Key playersSanofi, Pfizer Inc., AbbVie Inc., LEO Pharma A/S, Eli Lilly and Company and 6 more (see all)
Regulator in JapanPMDASource: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
Active clinical trials28 in JapanSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 9 Nov 2026.
FormatsPDF, PPTX, XLSX

Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.

The Japan Atopic Dermatitis Drugs Market Executive Summary

Atopic dermatitis, also known as eczema, is a chronic skin condition which involves inflammation, redness and itching. While its typical onset is in childhood, RA can develop at any age and is not transmissible from one person to another. They manifest as severe itching, skin redness, inflammation, and dermatitis with eruptive phases and quiescent periods. The exact reason is still unknown, but genetic and heredity, immune, and environment could play a role. It is treatable and while it tends to be worse in childhood, it tends to reduce in adulthood and can even cause some problems.
Globally, 2.6% of the population, or 204 million people, are affected by atopic dermatitis (AD). This includes approximately 101 million adults and 103 million children. Additionally, findings indicate that females are more commonly affected by AD than males. Interventions consist of the topical corticosteroids of triamcinolone (Kenalog, Aristocort A and others) and systemic immunosuppressive agents, which include cyclosporine and methotrexate. This sector is emerging due to the improvements in the treatments and awareness of the disease. There are more recent biologics such as Dupixent, and the pool of nonsteroidal topical agents is seen to grow with the inclusion of roflumilast. Interests remain high or are rising in innovative therapies and treatment approaches with increased attention to natural therapies and telemedicine for better disease management.

Bar chart: Japan Atopic Dermatitis Drugs market size, 2024–2034, placeholder estimates. $786.6 Mn in 2024, $886.6 Mn in 2025 and $2.60 Bn in 2034, 12.7% CAGR.
Japan Atopic Dermatitis Drugs market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.

Japan Atopic Dermatitis Drugs Market Dynamics

Market Growth Drivers

Atopic dermatitis is becoming more common in children and young adults, and this has led to the need for improvement in treatment options. Lifestyle changes, environmental factors, and heredity are some of the causes that could lead to this incidence. Newer agents including RINVOQ and Dupixent are more effective and safer for moderate to severe rheumatoid arthritis. Public awareness campaigns, like the World Atopic Eczema Day, and educational interventions are improving diagnosis and management. It is projected that the market will expand with novel biologics and small molecules, rising healthcare expenditures, and enhanced treatment availability, particularly in the developing world. Progress in technology is driving access of new treatments. The Asia Pacific region is expected to show the highest market growth based on factors such as improvement in health care access, increase in disposable income, and increase in health awareness.

Opportunity

The atopic dermatitis market has promising future prospects due to the emergence of new therapies. New nonsteroidal topical therapies like roflumilast and tapinarof and new biologics like lebrikizumab are also expected to expand patient choices, given approval. Awareness about atopic dermatitis and its psychological effects will enhance its diagnosis and treatment. Greater patient awareness and compliance with prescribed treatment plans will continue to expand the market. Opportunities include increased investment in biologics and new complex treatments and the adoption of telehealth and digital health solutions. There is also an increasing demand for natural and organic solutions. In conclusion, as the awareness and the need for management solutions rises, the market has the potential of growing significantly.

Market Restraints

High treatment costs for atopic dermatitis significantly limit patient access, discouraging therapy initiation and continuation due to financial burden. Regional differences in access to dermatological specialists further exacerbate this issue, with patients in areas with fewer specialists facing greater challenges. Complex treatment regimens and high costs often lead to poor adherence. As alternative treatments like herbal remedies gain popularity, traditional therapy providers may face decreased demand. Lack of awareness and inadequate diagnostic methods contribute to under-treatment and an increased disease burden.

Competitive Landscape for Atopic Dermatitis Drugs Market in Japan

Key Players

Recent Developments:

February 2024, The U.S. Food and Drug Administration (FDA) and the European Medicines Agency have accepted filing submissions for nemolizumab to treat prurigo nodularis and atopic dermatitis. Additionally, the FDA has granted nemolizumab Priority Review status for prurigo nodularis.

January 2024, Glenmark, Pfizer launch Abrocitinib in India for Atopic Dermatitis

January 2024, Vtama Is Getting Ready to Elbow Its Way into the Crowded Field of Atopic Dermatitis Medications

Mergers and Acquisitions

June 2024, Johnson & Johnson to Acquire Proteologix, Inc. to Lead in Atopic Dermatitis Treatment

2020, BMS's acquisition of MyoKardia was intended to enhance its cardiovascular portfolio, but it also signifies a broader strategy to diversify its therapeutic range, including dermatology products.

2020, AbbVie's acquisition of Allergan has notably strengthened its dermatology position by incorporating Allergan's skin care products and treatments, which complement AbbVie's existing atopic dermatitis offerings.

Healthcare Policies and Regulatory Landscape for Atopic Dermatitis Drugs Market in Japan

Atopic Dermatitis Drugs in Japan: rules, payment and research

Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW).⁠[1] Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices).⁠[2] ClinicalTrials.gov lists 28 studies on Atopic Dermatitis Drugs that are recruiting, active or about to start in Japan.⁠[3]

[1] Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.

[2] Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.

[3] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 9 Nov 2026.

Policy changes and Reimbursement scenario

Patients and clinicians are aware that regulatory agencies closely monitor the effectiveness and safety of atopic dermatitis therapies that can take time before new therapeutic options come into the market. However, in the case of severe atopic dermatitis, biologics are gradually receiving approvals from drug authorities, and research-based companies are enabling access to these state-of-the-art treatments. Due to drug escalation, the healthcare laws of many countries are being imposed to allow equitable insurance cover for dermatological expensive biologics. This is due to the fact that insurers are more concerned with the outcomes of the treatments rather than costs associated with such treatments and therefore reimbursement for such treatments is enhancing. Furthermore, patient assistance programs in pharmaceutical markets have also emerged to assist with out-of-pocket expenses however reimbursement is also different from country to country.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Atopic Dermatitis Drugs right now, from free public sources.

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 9 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Atopic Dermatitis Drugs in context

Japan compared

  • Health spending per person: 3,638 US$ per person (2023). World: 1,317 US$ per person (2023). 4th highest of the 15 countries we cover in APAC.[1]
  • Doctors: 2.65 per 1,000 people (2022). World: 1.86 per 1,000 people (2022). 5th highest of the 15 countries we cover in APAC.[2]
  • People aged 65 and over: 30.0% of people (2025). World: 10.4% of people (2025). Highest of the 16 countries we cover in APAC.[3]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 17 Nov 2026.

Free data on this topic

Quick answers

Frequently asked questions

How big is the Atopic Dermatitis Drugs market in Japan?
Placeholder estimate: about $886.6 Mn in 2025, rising to about $2.60 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Atopic Dermatitis Drugs market in Japan growing?
Placeholder estimate: about 12.7% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Atopic Dermatitis Drugs market report cover?
The report splits the market by drug class (Biologics, Corticosteroids, Calcineurin Inhibitors, PDE4 Inhibitors and more), route of administration (Topical, Injectable, Oral) and distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Dermatology Clinics).
Who are the key players in the Atopic Dermatitis Drugs market?
Key players include Sanofi, Pfizer Inc., AbbVie Inc., LEO Pharma A/S, Eli Lilly and Company and Teva Pharmaceutical, among 11 companies the report profiles.
What is driving the Atopic Dermatitis Drugs market?
Atopic dermatitis is becoming more common in children and young adults, and this has led to the need for improvement in treatment options. Lifestyle changes, environmental factors, and heredity are some of the causes that could lead to this incidence.
Who regulates Atopic Dermatitis Drugs in Japan?
Drugs are reviewed by the Pharmaceuticals and Medical Devices Agency (PMDA) and approved by the Ministry of Health, Labour and Welfare (MHLW). Source: Pharmaceuticals and Medical Devices Agency. Checked 14 Nov 2026.
How is healthcare paid for in Japan?
Everyone is covered by public health insurance, and the Ministry of Health, Labour and Welfare sets the official price list for covered medicines (NHI prices). Source: Ministry of Health, Labour and Welfare. Checked 14 Nov 2026.
How many clinical trials on Atopic Dermatitis Drugs are running in Japan?
28 studies are recruiting, active or about to start in Japan, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Japan. Retrieved 9 Nov 2026.
How much research is published on Atopic Dermatitis Drugs?
PubMed lists 15,446 papers on Atopic Dermatitis Drugs added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 9 Nov 2026.
Back to Catalogue

Related Pharmaceuticals reports in Japan

See all

Related on skin and hair and allergies

See the topic